LongeCityNews Last Updated: 20 March 2026 - 07:22 PM

A new study has found a negative association between unprocessed meat consumption and cognitive decline in carriers of the “pro-Alzheimer’s” APOE ε4 allele. This counterintuitive connection might have something to do with human evolution [1].

The meat connection

The APOE gene, which produces apolipoprotein E, a protein central to lipid transport in the brain and body, comes in three variants (alleles): ε2, ε3, and ε4. APOE genotypes are a massive risk factor for Alzheimer’s disease, with ε3 being the most common and “neutral,” ε2 the rarest and protective, and ε4 significantly increasing the risk, especially in homozygous (ε4/ε4) individuals.

Interestingly, ε4 is the ancestral human allele, emerging perhaps 1-6 million years ago; ε3 appeared about 200,000 years ago, and ε2 even later. Several hypotheses explain this by shifts in human diet, since APOE probably modifies responses to dietary factors. One such hypothesis proposes that early humans went through a “hypercarnivorous” phase millions of years ago, followed by a gradual return toward more plant-based eating [2]. The timing of ε4’s emergence may overlap with that meat-heavy period, while ε3 appeared as diets became more omnivorous again.

This hypothesis is supported by the fact that ε4’s modern distribution is most common in populations with historically meat-heavy diets [3]. Moreover, in some populations still leading traditional subsistence lifestyles, ε4 does not appear to carry the same cognitive penalties seen in Western populations and may even confer cognitive benefits [4].

In a new study from Karolinska Institutet in Sweden, the researchers looked at the 2,100-strong human cohort in the Swedish National Study on Aging and Care and matched the incidence of dementia and cognitive decline with the APOE genotype and meat consumption. Interestingly, Northern Europe has a relatively high ε4 frequency, whereas Southern Europe has the lowest. This gradient tracks well with the historical reliance on animal-based foods compared to grain-based agriculture.

Less cognitive decline and dementia for ε4 meat eaters

Participants in the study were followed for up to 15 years. Diet was assessed via a food-frequency questionnaire at baseline and at follow-ups. The cohort was predominantly Northern European and had a mean age of 71 years. The researchers divided the cohort into two subgroups: people with or without the ε4 allele. Since ε4 and ε2 alleles are rare, about 80% of the non-ε4 group consisted of people with the ε3/ε3 genotype, and about 90% of the ε4 group consisted of people with the ε3/ε4 genotype.

The primary model was adjusted for age, sex, education, APOE status, living arrangements (alone vs. not alone), occupation, physical activity, smoking, alcohol intake, total energy intake, Alternative Healthy Eating Index score, number of chronic diseases, and baseline cognition. The primary outcome was cognitive trajectory: the rate of change over 10 years of a global cognition score composed of episodic memory, semantic memory, verbal fluency, and perceptual speed. The secondary outcome was a dementia diagnosis.

Higher total meat consumption was associated with significantly better cognitive trajectories in the ε4 group but not in non-carriers. In quintile-based analyses, Q5 ε4 carriers performed similarly to non-carriers, meaning that the well-established genotype-associated cognition penalty was effectively erased at high meat consumption.

The effect was strongest for episodic memory, which notably declines in Alzheimer’s. Semantic memory, verbal fluency, and perceptual speed showed directionally consistent but weaker and non-significant interactions.

The red-meat-to-poultry ratio was unrelated to outcomes, meaning that it didn’t matter whether the unprocessed meat was red or white. A higher processed-to-total meat ratio was unfavorably associated with cognitive trajectory in ε4 carriers. While total and unprocessed meat appeared beneficial specifically for ε4 carriers, processed meat was either neutral or harmful regardless of genotype.

Among ε4 carriers, Q5 vs Q1 of total meat consumption was associated with a 55% lower dementia risk. However, the APOE interaction for dementia did not reach statistical significance, so it cannot be ruled out that the effect of meat consumption on dementia incidence is not specific to ε4 carriers (although the data trended that way). Processed meat appeared unfavorable for dementia regardless of the genotype.

Higher unprocessed meat consumption was also associated with 15% lower all-cause mortality specifically in ε4 carriers. If meat simply reduced survival in ε4 carriers in ways unrelated to dementia, hence causing them to die before developing the disease, this would provide false evidence that meat protects from dementia. The mortality finding rules this artifact out. In good news for pescatarians, further analyses suggested that the cognitive benefit for ε4 carriers was preserved when meat was replaced with fish.

Reinforcement from two large cohorts

The authors identified concordant patterns in two large previously published studies. In the UK Biobank, unprocessed red meat was inversely associated with dementia overall, but this was driven by ε4 carriers [5]. In the Nurses’ Health Study and Health Professionals Follow-up Study, supplementary analyses revealed a significant ε4 interaction for unprocessed red meat, with favorable trends among carriers and adverse trends among non-carriers [6].

“Those who ate more meat overall had significantly slower cognitive decline and a lower risk of dementia, but only if they had the APOE 3/4 or 4/4 gene variants,” said first author Jakob Norgren, researcher at the Department of Neurobiology, Care Sciences and Society, Karolinska Institutet. “There is a lack of dietary research into brain health, and our findings suggest that conventional dietary advice may be unfavorable to a genetically defined subgroup of the population. Since the prevalence of APOE4 is about twice as high in the Nordic countries as in the Mediterranean countries, we are particularly well suited to conduct research on tailored dietary recommendations for this risk group.”

Literature

[1] Norgren J, Carballo-Casla A, Grande G, et al. (2026). Meat Consumption and Cognitive Health by APOE Genotype. JAMA Netw Open, 9(3):e266489.

[2] Ben‐Dor, M., Sirtoli, R., & Barkai, R. (2021). The evolution of the human trophic level during the Pleistocene. American journal of physical anthropology, 175, 27-56.

[3] Singh, P. P., Singh, M., & Mastana, S. S. (2006). APOE distribution in world populations with new data from India and the UK. Annals of human biology, 33(3), 279-308.

[4] Trumble, B. C., Stieglitz, J., Blackwell, A. D., Allayee, H., Beheim, B., Finch, C. E., … & Kaplan, H. (2016). Apolipoprotein E4 is associated with improved cognitive function in Amazonian forager-horticulturalists with a high parasite burden. The FASEB journal, 31(4), 1508.

[5] Zhang, H., Greenwood, D. C., Risch, H. A., Bunce, D., Hardie, L. J., & Cade, J. E. (2021). Meat consumption and risk of incident dementia: cohort study of 493,888 UK Biobank participants. The American journal of clinical nutrition, 114(1), 175-184.

[6] Li, Y., Li, Y., Gu, X., Liu, Y., Dong, D., Kang, J. H., … & Wang, D. (2025). Long-term intake of red meat in relation to dementia risk and cognitive function in US adults. Neurology, 104(3), e210286.

Aging can be split up into specific categories in many different ways; age-related diseases as collections of symptoms, specific forms of cell and tissue damage that accumulate, dysfunctions separated by organ, and so forth. None of these categories exist in isolation from the others, however. All aspects of aging interact with one another. Kidney dysfunction affects the brain. Mitochondrial dysfunction influences the burden of cellular senescence. There are a hundred other interactions one might consider that blur the lines of any attempt at categorization of the progression of aging. Nothing is neat and contained, everything interacts.

Aging is accompanied by conserved hallmarks including genomic instability, epigenetic alterations, loss of proteostasis, and mitochondrial dysfunction, but how these processes emerge and become mechanistically linked remains unclear. Here we leverage a proteome-wide, single-cell, subcellular atlas of protein expression, localization, and aggregation across yeast replicative aging to map hallmark-linked remodeling in its spatial context.

We identify hundreds of previously unappreciated molecular changes that underlie major hallmarks of aging and show that hallmark phenotypes frequently manifest as compartment-specific erosion of spatial confinement, relocalization, and aggregation. 91.6% human orthologs of these hallmark-linked yeast proteins also change during human aging. Integrating these spatial phenotypes reveals many molecular connections linking different hallmarks. Temporal analysis suggests that disorganization of nucleolar ribosome biogenesis, proteostasis decline, and mitochondrial dysfunction precede other hallmarks. Together, our findings substantially deepen the molecular underpinnings of aging hallmarks and provide a framework for linking them into a hierarchical sequence of cellular failures.

Link: https://doi.org/10.64898/2026.02.26.708335

Sarcopenia is the name given to the characteristic age-related loss of muscle mass and strength, once the process enters more severe stages. The loss of strength and resilience is an important contribution to frailty, but muscle is also a metabolically active tissue and loss of muscle negatively affects metabolism as well as physical capacity. Chronic inflammation is a feature of aging, as the immune system reacts to cell and tissue dysfunction in maladaptive ways. That chronic inflammation contributes to all of the common age-related conditions by interfering in the maintenance of tissues; this includes muscle tissue and the development of sarcopenia.

Sarcopenia is a syndrome characterized by an age-related progressive decline in skeletal muscle mass, strength, and function. It represents a significant public health concern because of its adverse impact on the quality of life and prognosis of older adults. Chronic low-grade inflammation contributes to the pathophysiology of sarcopenia through multiple pathways, including cellular senescence, immunosenescence, oxidative stress, mitochondrial dysfunction, hormonal alterations, and gut microbiota dysbiosis. Moreover, obesity, a chronic inflammatory condition, is associated with sarcopenia, leading to sarcopenic obesity, which further exacerbates muscle loss and functional impairment.

In terms of interventions, exercise, nutritional supplementation, and combined approaches have demonstrated efficacy in improving muscle mass and function, as well as conferring demonstrable anti-inflammatory benefits. In addition to conventional hormonal therapies, pharmacological strategies, particularly anti-inflammatory agents and treatments targeting inflammatory pathways, show considerable therapeutic promise.

This review examines the central role of chronic inflammation in the development and progression of sarcopenia, as well as its underlying mechanistic basis. It also elaborates on the roles of key inflammatory cytokines, such as C-reactive protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α), in regulating muscle protein metabolic balance and their potential utility as biomarkers. A deeper understanding of the relationship between inflammation and sarcopenia will not only help elucidate its complex pathogenesis but also offer critical directions for the future development of early diagnostic tools and targeted anti-inflammatory interventions.

Link: https://doi.org/10.3389/fphar.2026.1733798

Senescent cells accumulate with age in tissues throughout the body, the result of a growing imbalance between the pace at which somatic cells enter the senescent state in response to damage, stress, and the Hayflick limit on the one hand and the pace of clearance of senescent cells by the immune system on the other. The growing burden of senescent cells disrupts tissue structure and function via inflammatory signaling. This is thought to produce a significant, important contribution to degenerative aging, and over the past fifteen years cellular senescence has become major focus of life science research and development.

Today the field of senotherapeutics, meaning anti-aging therapies that in some way target senescent cells, is in the strange superimposed state of both existing and yet to emerge. Senostatics slow the rate at which cells become senescent, and the low cost, generic mTOR inhibitor rapamycin appears to be a legitimate senostatic. Senolytics selectively destroy senescent cells, and the senolytic combination of dasatinib and quercetin, the subject of several early stage clinical trials, also costs little. Senomorphics impede the bad behavior of senescent cells, and many existing drugs might qualify as senomorphic to some degree.

The two named options above are readily available via off-label prescription to any older individual willing to try. Yet use is not widespread. The large clinical trials that would provide concrete demonstrations of efficacy (or lack of same) have not been conducted, and do not seem likely to be conducted. Generic drugs cannot command enough revenue to support the regulatory cost of large clinical trials. The research community and longevity industry is instead focused on the development of a wide range of novel senotherapeutics, and progress largely remains at a preclinical stage. Today's open access paper is an opinionated tour, but gives a sense of where things stand, the variety of approaches under consideration.

Emerging strategies in senotherapeutics: from broad-spectrum senolysis to precision reprogramming

Cellular senescence, originally described as a finite proliferative arrest in cultured somatic cells, has since been recognized as a central mechanism underlying aging and the development of age-associated disorders. The progressive accumulation of senescent cells (SnCs) promotes chronic inflammation through the senescence-associated secretory phenotype (SASP) and circumvents immune-mediated clearance by upregulating pro-survival and immune checkpoint pathways. Early "first-generation" senolytics, including navitoclax (ABT-263) and the dasatinib-quercetin (D + Q) combination, provided proof-of-concept that selective removal of SnCs can alleviate certain fibrotic, metabolic, and cardiovascular pathologies in preclinical studies. However, these agents exhibited notable drawbacks, such as dose-dependent thrombocytopenia, variable therapeutic efficacy, and the emergence of resistance mechanisms. Consequently, current research has shifted toward precision senotherapy, though significant translational challenges remain.

This review synthesizes three next-generation strategies developed to address limitations of early senolytic agents. (1) Immune-based senolysis: This approach applies immuno-oncology principles to counter immune evasion of SnCs. Strategies include blocking immunosuppressive ligands such as GD3 ganglioside, engineering chimeric antigen receptor (CAR) T cells to target senescence-specific surface markers like urokinase-type plasminogen activator receptor (uPAR), and exploiting metabolic vulnerabilities (e.g., glutaminolysis and ferroptosis) to sensitize SnCs to immune-mediated clearance. (2) Tissue-precision proteolysis-targeting chimeras (PROTACs): These agents recruit organ- or tissue-specific E3 ligases (e.g., von Hippel-Lindau (VHL)) to selectively degrade anti-apoptotic proteins such as BCL-xL. Localized activity may reduce systemic toxicity and mitigate dose-limiting effects observed with traditional inhibitors. (3) Microbiome-epigenetic interplay: This strategy modulates the gut-liver axis to enhance senolytic efficacy. Short-chain fatty acids (SCFAs), such as butyrate, epigenetically regulate drug transporter expression and suppress the SASP, while dietary interventions may create a microenvironment favorable to senolysis.

These approaches offer potentially more targeted and personalized therapeutic options but face significant challenges, including immunopathology, manufacturing complexity, off-target effects, and long-term safety concerns. The ongoing shift from broad inhibition to precision reprogramming represents a promising but preliminary step in the treatment of age-related diseases.